AstraZeneca – Lupus collaboration
A breakthrough treatment for the autoimmune disease systemic lupus erythematosus (SLE or lupus) was announced in November 2019 by Professor Eric Morand, head of the School of Clinical Sciences at Monash Health.
The AstraZeneca monoclonal antibody anifrolumab was shown in Phase 3 clinical trials to achieve a statistically significant reduction in disease activity versus a placebo, offering real hope for a disease that affects 20,000 young Australian women. The company is working with regulators to bring anifrolumab to patients.
Read more: